Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically, cytologically or clinically diagnosed (in patient with cirrhosis, Alpha-Fetoprotein(AFP)≥400μg/L and morphological evidence \[contrast Computed Tomography(CT)/Magnetic Resonance Imaging(MRI)\] of hypervascular liver tumor, elevated AFP level due to other reasons \[germ cell carcinoma, progressive chronic hepatitis, pregnancy, etc\] can be excluded) unresectable hepatocellular carcinoma, ineligible or if the patient does not consent to receive local invasive treatment (chemo-embolism, ablation, etc.).~* At least one measurable lesion (on CT: ≥2cm, on spiral CT or MRI ≥1cm)~* Have not received previous palliative systemic chemotherapy for metastatic disease. If the patient received previous systemic chemotherapy as adjuvant treatment, he must have been completed at least 12 months previously.~* Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 8 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion.~* Karnofsky Performance Score≥70, Barcelona of Cancer Liver Category stage B/C~* Patients must have adequate organ and marrow function:~  * Neutrophilus≥1.5X10\^9/L~ * Platelets≥75X10\^9/L~ * Asparagine AminoTransferase,Alanine AminoTransferase\<2.5 Upper Normal Limit(UNL)~ * Total Bilirubin\<1.5 UNL~ * International Normalized Ratio\<1.5~ * Child stage A or B~ * Normal base line Left Ventricular Ejection Fraction (LVEF result must be above or equal to the lower limit of normal for the institution)~Exclusion Criteria:~* Documented allergy to platinum compound or to other study drugs.~* Any previous oxaliplatin or doxorubicin treatment, except adjuvant treatment more than 12 months before the randomization.~* Previous liver transplantation.~* Patients concomitantly receiving any other anti-cancer therapy, including interferon-α and herbal medicine which was approved by local authority to be used as anti-cancer medicine, except radiotherapy to non-target lesion (bone metastasis, etc)~* Patients who are receiving any other study treatments.~* Pregnant or lactating women or women of childbearing potential without proper contraceptive methods.~* History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.~* Central nervous system metastasis~* Other serious illness or medical conditions~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Oxaliplatin + 5-Fluorouracil/Leucovorin
- B (Type: ACTIVE_COMPARATOR): Doxorubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).